Placebo + Ticagrelor vs Aspirin + Ticagrelor: Number of Participants With BARC Type 2, 3, or 5
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0397 | 0.0337 | 0.0466 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0701 | 0.0622 | 0.079 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0305 | -0.0411 | -0.02 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.565 | 0.462 | 0.691 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.547 | 0.443 | 0.677 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Placebo + Ticagrelor than on Aspirin + Ticagrelor | 32.8 | 24.3 | 50.1 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Placebo + Ticagrelor | placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months | 141 | 3,555 | OG000 | ClinicalTrials.gov |
| Group 2 | Aspirin + Ticagrelor | enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months | 250 | 3,564 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Number of Participants With BARC Type 2, 3, or 5 | ClinicalTrials.gov |
| Description | Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). | ClinicalTrials.gov |
| Time frame | 12 months after randomization | ClinicalTrials.gov |
| Population | Data for the intention-to-treat population | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention | ClinicalTrials.gov |
| NCT number | NCT02270242 | ClinicalTrials.gov |
| Phases | PHASE4 | ClinicalTrials.gov |
| Conditions | Cardiovascular Disease, Interventional Cardiology | ClinicalTrials.gov |
| Interventions | Aspirin, Placebo, ticagrelor | ClinicalTrials.gov |
| Lead sponsor | Icahn School of Medicine at Mount Sinai | ClinicalTrials.gov |
| Results first posted | 2020-08-19 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02270242?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.